Business Description
ANI Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US00182C1036
Share Class Description:
ANIP: Ordinary SharesTotal Employee Number:
970Compare
Compare
Traded in other countries / regions
ANIP.USABSFA.Germany Index Membership
Russell 2000Russell 3000 IPO Date
1999-09-13Description
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 1.09 | |||||
Debt-to-EBITDA | 2.74 | |||||
Interest Coverage | 5.77 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.74 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 28.8 | |||||
3-Year EBITDA Growth Rate | 85.1 | |||||
3-Year EPS without NRI Growth Rate | 79.7 | |||||
3-Year Book Growth Rate | 10.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.69 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.24 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.62 | |||||
9-Day RSI | 65.75 | |||||
14-Day RSI | 60.99 | |||||
3-1 Month Momentum % | 9.81 | |||||
6-1 Month Momentum % | -1.21 | |||||
12-1 Month Momentum % | 23.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.12 | |||||
Quick Ratio | 2.52 | |||||
Cash Ratio | 1.36 | |||||
Days Inventory | 142.98 | |||||
Days Sales Outstanding | 97.61 | |||||
Days Payable | 62.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.7 | |||||
Shareholder Yield % | -3.07 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.83 | |||||
Operating Margin % | 11.46 | |||||
Net Margin % | 9.98 | |||||
EBITDA Margin % | 24.23 | |||||
FCF Margin % | 19.79 | |||||
OCF Margin % | 22.58 | |||||
ROE % | 18.33 | |||||
ROA % | 6.67 | |||||
ROIC % | 8.64 | |||||
3-Year ROIIC % | 27.3 | |||||
ROC (Joel Greenblatt) % | 54.78 | |||||
ROCE % | 11.83 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.39 | |||||
Forward PE Ratio | 8.98 | |||||
PE Ratio without NRI | 14.77 | |||||
Price-to-Owner-Earnings | 10.56 | |||||
PEG Ratio | 0.25 | |||||
PS Ratio | 1.95 | |||||
PB Ratio | 3.44 | |||||
Price-to-Tangible-Book | 59.08 | |||||
Price-to-Free-Cash-Flow | 9.73 | |||||
Price-to-Operating-Cash-Flow | 8.53 | |||||
EV-to-EBIT | 16.44 | |||||
EV-to-Forward-EBIT | 9.19 | |||||
EV-to-EBITDA | 9.87 | |||||
EV-to-Forward-EBITDA | 8.5 | |||||
EV-to-Revenue | 2.39 | |||||
EV-to-Forward-Revenue | 1.98 | |||||
EV-to-FCF | 12.08 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Projected-FCF | 1.85 | |||||
Price-to-Median-PS-Value | 0.83 | |||||
Price-to-Graham-Number | 6.23 | |||||
Earnings Yield (Greenblatt) % | 6.08 | |||||
FCF Yield % | 9.52 | |||||
Forward Rate of Return (Yacktman) % | -22.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANIP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ANI Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 923.706 | ||
| EPS (TTM) ($) | 3.95 | ||
| Beta | -0.0327 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.12 | ||
| Volatility % | 52.2 | ||
| 14-Day RSI | 60.99 | ||
| 14-Day ATR ($) | 2.615931 | ||
| 20-Day SMA ($) | 80.5615 | ||
| 12-1 Month Momentum % | 23.7 | ||
| 52-Week Range ($) | 62.605 - 99.5 | ||
| Shares Outstanding (Mil) | 22.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ANI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ANI Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 132 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | In 41 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 40 days | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-03 15:45 | 74.65 (-1.56%) | ||
| General meeting for 2026 | 2026-05-21 09:00 | 82.00 (+1.35%) | ||
| First quarter earnings conference call for 2026 | 2026-05-08 08:00 | 83.91 (-0.32%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 83.91 (-0.32%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 15:00 | 75.96 (+1.70%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 15:00 | 74.80 (+1.31%) |
Show
Entries
ANI Pharmaceuticals Inc Frequently Asked Questions
What is ANI Pharmaceuticals Inc(ANIP)'s stock price today?
The current price of ANIP is $84.49. The 52 week high of ANIP is $99.50 and 52 week low is $62.61.
When is next earnings date of ANI Pharmaceuticals Inc(ANIP)?
The next earnings date of ANI Pharmaceuticals Inc(ANIP) is 2026-08-07 Est..
Does ANI Pharmaceuticals Inc(ANIP) pay dividends? If so, how much?
ANI Pharmaceuticals Inc(ANIP) does not pay dividend.
Guru Commentaries on NAS:ANIP
No articles.
Press Release
Articles on ANI Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers